line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,THEMISMED.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.248069,THEMISMED.NS
Normalized EBITDA,2025-03-31 00:00:00,596431000.0,THEMISMED.NS
Total Unusual Items,2025-03-31 00:00:00,,THEMISMED.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,,THEMISMED.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,298330000.0,THEMISMED.NS
Reconciled Depreciation,2025-03-31 00:00:00,99287000.0,THEMISMED.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,1319906000.0,THEMISMED.NS
EBITDA,2025-03-31 00:00:00,596431000.0,THEMISMED.NS
EBIT,2025-03-31 00:00:00,497144000.0,THEMISMED.NS
Net Interest Income,2025-03-31 00:00:00,-100395000.0,THEMISMED.NS
Interest Expense,2025-03-31 00:00:00,100395000.0,THEMISMED.NS
Interest Income,2025-03-31 00:00:00,,THEMISMED.NS
Normalized Income,2025-03-31 00:00:00,298330000.0,THEMISMED.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,298330000.0,THEMISMED.NS
Total Expenses,2025-03-31 00:00:00,3663921000.0,THEMISMED.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,THEMISMED.NS
Diluted Average Shares,2025-03-31 00:00:00,92077160.0,THEMISMED.NS
Basic Average Shares,2025-03-31 00:00:00,92077160.0,THEMISMED.NS
Diluted EPS,2025-03-31 00:00:00,3.24,THEMISMED.NS
Basic EPS,2025-03-31 00:00:00,3.24,THEMISMED.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,298330000.0,THEMISMED.NS
Average Dilution Earnings,2025-03-31 00:00:00,,THEMISMED.NS
Net Income Common Stockholders,2025-03-31 00:00:00,298330000.0,THEMISMED.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,THEMISMED.NS
Net Income,2025-03-31 00:00:00,298330000.0,THEMISMED.NS
Minority Interests,2025-03-31 00:00:00,2000.0,THEMISMED.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,298328000.0,THEMISMED.NS
Net Income Continuous Operations,2025-03-31 00:00:00,298328000.0,THEMISMED.NS
Tax Provision,2025-03-31 00:00:00,98421000.0,THEMISMED.NS
Pretax Income,2025-03-31 00:00:00,396749000.0,THEMISMED.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,46695000.0,THEMISMED.NS
Special Income Charges,2025-03-31 00:00:00,,THEMISMED.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-100395000.0,THEMISMED.NS
Total Other Finance Cost,2025-03-31 00:00:00,,THEMISMED.NS
Interest Expense Non Operating,2025-03-31 00:00:00,100395000.0,THEMISMED.NS
Interest Income Non Operating,2025-03-31 00:00:00,,THEMISMED.NS
Operating Income,2025-03-31 00:00:00,391195000.0,THEMISMED.NS
Operating Expense,2025-03-31 00:00:00,2344015000.0,THEMISMED.NS
Other Operating Expenses,2025-03-31 00:00:00,1280970000.0,THEMISMED.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,99287000.0,THEMISMED.NS
Amortization,2025-03-31 00:00:00,,THEMISMED.NS
Depreciation Income Statement,2025-03-31 00:00:00,99287000.0,THEMISMED.NS
Selling General And Administration,2025-03-31 00:00:00,,THEMISMED.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,THEMISMED.NS
General And Administrative Expense,2025-03-31 00:00:00,,THEMISMED.NS
Rent And Landing Fees,2025-03-31 00:00:00,,THEMISMED.NS
Gross Profit,2025-03-31 00:00:00,2735210000.0,THEMISMED.NS
Cost Of Revenue,2025-03-31 00:00:00,1319906000.0,THEMISMED.NS
Total Revenue,2025-03-31 00:00:00,4055116000.0,THEMISMED.NS
Operating Revenue,2025-03-31 00:00:00,4055116000.0,THEMISMED.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,THEMISMED.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.185612,THEMISMED.NS
Normalized EBITDA,2024-03-31 00:00:00,750661000.0,THEMISMED.NS
Total Unusual Items,2024-03-31 00:00:00,0.0,THEMISMED.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,0.0,THEMISMED.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,435238000.0,THEMISMED.NS
Reconciled Depreciation,2024-03-31 00:00:00,122463000.0,THEMISMED.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,1367137000.0,THEMISMED.NS
EBITDA,2024-03-31 00:00:00,750661000.0,THEMISMED.NS
EBIT,2024-03-31 00:00:00,628198000.0,THEMISMED.NS
Net Interest Income,2024-03-31 00:00:00,-93766000.0,THEMISMED.NS
Interest Expense,2024-03-31 00:00:00,93766000.0,THEMISMED.NS
Interest Income,2024-03-31 00:00:00,8393000.0,THEMISMED.NS
Normalized Income,2024-03-31 00:00:00,435238000.0,THEMISMED.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,435238000.0,THEMISMED.NS
Total Expenses,2024-03-31 00:00:00,3425019000.0,THEMISMED.NS
Rent Expense Supplemental,2024-03-31 00:00:00,21692000.0,THEMISMED.NS
Diluted Average Shares,2024-03-31 00:00:00,92211441.0,THEMISMED.NS
Basic Average Shares,2024-03-31 00:00:00,92016490.0,THEMISMED.NS
Diluted EPS,2024-03-31 00:00:00,4.72,THEMISMED.NS
Basic EPS,2024-03-31 00:00:00,4.73,THEMISMED.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,435238000.0,THEMISMED.NS
Average Dilution Earnings,2024-03-31 00:00:00,0.0,THEMISMED.NS
Net Income Common Stockholders,2024-03-31 00:00:00,435238000.0,THEMISMED.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,THEMISMED.NS
Net Income,2024-03-31 00:00:00,435238000.0,THEMISMED.NS
Minority Interests,2024-03-31 00:00:00,3000.0,THEMISMED.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,435235000.0,THEMISMED.NS
Net Income Continuous Operations,2024-03-31 00:00:00,435235000.0,THEMISMED.NS
Tax Provision,2024-03-31 00:00:00,99197000.0,THEMISMED.NS
Pretax Income,2024-03-31 00:00:00,534432000.0,THEMISMED.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,47555000.0,THEMISMED.NS
Special Income Charges,2024-03-31 00:00:00,0.0,THEMISMED.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-93766000.0,THEMISMED.NS
Total Other Finance Cost,2024-03-31 00:00:00,17491000.0,THEMISMED.NS
Interest Expense Non Operating,2024-03-31 00:00:00,93766000.0,THEMISMED.NS
Interest Income Non Operating,2024-03-31 00:00:00,8393000.0,THEMISMED.NS
Operating Income,2024-03-31 00:00:00,392589000.0,THEMISMED.NS
Operating Expense,2024-03-31 00:00:00,2057882000.0,THEMISMED.NS
Other Operating Expenses,2024-03-31 00:00:00,1111315000.0,THEMISMED.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,122463000.0,THEMISMED.NS
Amortization,2024-03-31 00:00:00,2184000.0,THEMISMED.NS
Depreciation Income Statement,2024-03-31 00:00:00,122463000.0,THEMISMED.NS
Selling General And Administration,2024-03-31 00:00:00,332569000.0,THEMISMED.NS
Selling And Marketing Expense,2024-03-31 00:00:00,223590000.0,THEMISMED.NS
General And Administrative Expense,2024-03-31 00:00:00,108979000.0,THEMISMED.NS
Rent And Landing Fees,2024-03-31 00:00:00,21692000.0,THEMISMED.NS
Gross Profit,2024-03-31 00:00:00,2450471000.0,THEMISMED.NS
Cost Of Revenue,2024-03-31 00:00:00,1367137000.0,THEMISMED.NS
Total Revenue,2024-03-31 00:00:00,3817608000.0,THEMISMED.NS
Operating Revenue,2024-03-31 00:00:00,3817608000.0,THEMISMED.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,113905.678695,THEMISMED.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.215323,THEMISMED.NS
Normalized EBITDA,2023-03-31 00:00:00,909470000.0,THEMISMED.NS
Total Unusual Items,2023-03-31 00:00:00,529000.0,THEMISMED.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,529000.0,THEMISMED.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,569010000.0,THEMISMED.NS
Reconciled Depreciation,2023-03-31 00:00:00,104948000.0,THEMISMED.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,1209968000.0,THEMISMED.NS
EBITDA,2023-03-31 00:00:00,909999000.0,THEMISMED.NS
EBIT,2023-03-31 00:00:00,805051000.0,THEMISMED.NS
Net Interest Income,2023-03-31 00:00:00,-90171000.0,THEMISMED.NS
Interest Expense,2023-03-31 00:00:00,79902000.0,THEMISMED.NS
Interest Income,2023-03-31 00:00:00,5473000.0,THEMISMED.NS
Normalized Income,2023-03-31 00:00:00,568594905.678695,THEMISMED.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,569010000.0,THEMISMED.NS
Total Expenses,2023-03-31 00:00:00,2874989000.0,THEMISMED.NS
Rent Expense Supplemental,2023-03-31 00:00:00,18077000.0,THEMISMED.NS
Diluted Average Shares,2023-03-31 00:00:00,92180107.0,THEMISMED.NS
Basic Average Shares,2023-03-31 00:00:00,92027700.0,THEMISMED.NS
Diluted EPS,2023-03-31 00:00:00,6.17,THEMISMED.NS
Basic EPS,2023-03-31 00:00:00,6.18,THEMISMED.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,569008000.0,THEMISMED.NS
Average Dilution Earnings,2023-03-31 00:00:00,0.0,THEMISMED.NS
Net Income Common Stockholders,2023-03-31 00:00:00,569010000.0,THEMISMED.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,THEMISMED.NS
Net Income,2023-03-31 00:00:00,569010000.0,THEMISMED.NS
Minority Interests,2023-03-31 00:00:00,2000.0,THEMISMED.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,569008000.0,THEMISMED.NS
Net Income Continuous Operations,2023-03-31 00:00:00,569008000.0,THEMISMED.NS
Tax Provision,2023-03-31 00:00:00,156141000.0,THEMISMED.NS
Pretax Income,2023-03-31 00:00:00,725149000.0,THEMISMED.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,34726000.0,THEMISMED.NS
Special Income Charges,2023-03-31 00:00:00,0.0,THEMISMED.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,-90171000.0,THEMISMED.NS
Total Other Finance Cost,2023-03-31 00:00:00,15742000.0,THEMISMED.NS
Interest Expense Non Operating,2023-03-31 00:00:00,79902000.0,THEMISMED.NS
Interest Income Non Operating,2023-03-31 00:00:00,5473000.0,THEMISMED.NS
Operating Income,2023-03-31 00:00:00,569561000.0,THEMISMED.NS
Operating Expense,2023-03-31 00:00:00,1665021000.0,THEMISMED.NS
Other Operating Expenses,2023-03-31 00:00:00,715479000.0,THEMISMED.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,104948000.0,THEMISMED.NS
Amortization,2023-03-31 00:00:00,2184000.0,THEMISMED.NS
Depreciation Income Statement,2023-03-31 00:00:00,102764000.0,THEMISMED.NS
Selling General And Administration,2023-03-31 00:00:00,263747000.0,THEMISMED.NS
Selling And Marketing Expense,2023-03-31 00:00:00,170302000.0,THEMISMED.NS
General And Administrative Expense,2023-03-31 00:00:00,93445000.0,THEMISMED.NS
Rent And Landing Fees,2023-03-31 00:00:00,18077000.0,THEMISMED.NS
Gross Profit,2023-03-31 00:00:00,2234582000.0,THEMISMED.NS
Cost Of Revenue,2023-03-31 00:00:00,1209968000.0,THEMISMED.NS
Total Revenue,2023-03-31 00:00:00,3444550000.0,THEMISMED.NS
Operating Revenue,2023-03-31 00:00:00,3444550000.0,THEMISMED.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,79646.246142,THEMISMED.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.234945,THEMISMED.NS
Normalized EBITDA,2022-03-31 00:00:00,1112448000.0,THEMISMED.NS
Total Unusual Items,2022-03-31 00:00:00,339000.0,THEMISMED.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,339000.0,THEMISMED.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,728808000.0,THEMISMED.NS
Reconciled Depreciation,2022-03-31 00:00:00,94798000.0,THEMISMED.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,1519946000.0,THEMISMED.NS
EBITDA,2022-03-31 00:00:00,1112787000.0,THEMISMED.NS
EBIT,2022-03-31 00:00:00,1017989000.0,THEMISMED.NS
Net Interest Income,2022-03-31 00:00:00,-81690000.0,THEMISMED.NS
Interest Expense,2022-03-31 00:00:00,65369000.0,THEMISMED.NS
Interest Income,2022-03-31 00:00:00,6055000.0,THEMISMED.NS
Normalized Income,2022-03-31 00:00:00,728548646.246142,THEMISMED.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,728808000.0,THEMISMED.NS
Total Expenses,2022-03-31 00:00:00,3051928000.0,THEMISMED.NS
Rent Expense Supplemental,2022-03-31 00:00:00,9794000.0,THEMISMED.NS
Diluted Average Shares,2022-03-31 00:00:00,92175350.0,THEMISMED.NS
Basic Average Shares,2022-03-31 00:00:00,92002700.0,THEMISMED.NS
Diluted EPS,2022-03-31 00:00:00,7.907,THEMISMED.NS
Basic EPS,2022-03-31 00:00:00,7.922,THEMISMED.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,728808000.0,THEMISMED.NS
Average Dilution Earnings,2022-03-31 00:00:00,,THEMISMED.NS
Net Income Common Stockholders,2022-03-31 00:00:00,728808000.0,THEMISMED.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,THEMISMED.NS
Net Income,2022-03-31 00:00:00,728808000.0,THEMISMED.NS
Minority Interests,2022-03-31 00:00:00,1000.0,THEMISMED.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,728807000.0,THEMISMED.NS
Net Income Continuous Operations,2022-03-31 00:00:00,728807000.0,THEMISMED.NS
Tax Provision,2022-03-31 00:00:00,223813000.0,THEMISMED.NS
Pretax Income,2022-03-31 00:00:00,952620000.0,THEMISMED.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,12646000.0,THEMISMED.NS
Special Income Charges,2022-03-31 00:00:00,0.0,THEMISMED.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-81690000.0,THEMISMED.NS
Total Other Finance Cost,2022-03-31 00:00:00,22376000.0,THEMISMED.NS
Interest Expense Non Operating,2022-03-31 00:00:00,65369000.0,THEMISMED.NS
Interest Income Non Operating,2022-03-31 00:00:00,6055000.0,THEMISMED.NS
Operating Income,2022-03-31 00:00:00,861552000.0,THEMISMED.NS
Operating Expense,2022-03-31 00:00:00,1531982000.0,THEMISMED.NS
Other Operating Expenses,2022-03-31 00:00:00,661814000.0,THEMISMED.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,94798000.0,THEMISMED.NS
Amortization,2022-03-31 00:00:00,2184000.0,THEMISMED.NS
Depreciation Income Statement,2022-03-31 00:00:00,92614000.0,THEMISMED.NS
Selling General And Administration,2022-03-31 00:00:00,278512000.0,THEMISMED.NS
Selling And Marketing Expense,2022-03-31 00:00:00,179291000.0,THEMISMED.NS
General And Administrative Expense,2022-03-31 00:00:00,99221000.0,THEMISMED.NS
Rent And Landing Fees,2022-03-31 00:00:00,9794000.0,THEMISMED.NS
Gross Profit,2022-03-31 00:00:00,2393534000.0,THEMISMED.NS
Cost Of Revenue,2022-03-31 00:00:00,1519946000.0,THEMISMED.NS
Total Revenue,2022-03-31 00:00:00,3913480000.0,THEMISMED.NS
Operating Revenue,2022-03-31 00:00:00,3913480000.0,THEMISMED.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,THEMISMED.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,THEMISMED.NS
Normalized EBITDA,2021-03-31 00:00:00,,THEMISMED.NS
Total Unusual Items,2021-03-31 00:00:00,188000.0,THEMISMED.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,188000.0,THEMISMED.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,THEMISMED.NS
Reconciled Depreciation,2021-03-31 00:00:00,,THEMISMED.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,THEMISMED.NS
EBITDA,2021-03-31 00:00:00,,THEMISMED.NS
EBIT,2021-03-31 00:00:00,,THEMISMED.NS
Net Interest Income,2021-03-31 00:00:00,,THEMISMED.NS
Interest Expense,2021-03-31 00:00:00,,THEMISMED.NS
Interest Income,2021-03-31 00:00:00,4121000.0,THEMISMED.NS
Normalized Income,2021-03-31 00:00:00,,THEMISMED.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,THEMISMED.NS
Total Expenses,2021-03-31 00:00:00,,THEMISMED.NS
Rent Expense Supplemental,2021-03-31 00:00:00,8338000.0,THEMISMED.NS
Diluted Average Shares,2021-03-31 00:00:00,,THEMISMED.NS
Basic Average Shares,2021-03-31 00:00:00,,THEMISMED.NS
Diluted EPS,2021-03-31 00:00:00,,THEMISMED.NS
Basic EPS,2021-03-31 00:00:00,,THEMISMED.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,THEMISMED.NS
Average Dilution Earnings,2021-03-31 00:00:00,,THEMISMED.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,THEMISMED.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,THEMISMED.NS
Net Income,2021-03-31 00:00:00,,THEMISMED.NS
Minority Interests,2021-03-31 00:00:00,,THEMISMED.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,THEMISMED.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,THEMISMED.NS
Tax Provision,2021-03-31 00:00:00,,THEMISMED.NS
Pretax Income,2021-03-31 00:00:00,,THEMISMED.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,THEMISMED.NS
Special Income Charges,2021-03-31 00:00:00,0.0,THEMISMED.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,THEMISMED.NS
Total Other Finance Cost,2021-03-31 00:00:00,17468000.0,THEMISMED.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,THEMISMED.NS
Interest Income Non Operating,2021-03-31 00:00:00,4121000.0,THEMISMED.NS
Operating Income,2021-03-31 00:00:00,,THEMISMED.NS
Operating Expense,2021-03-31 00:00:00,,THEMISMED.NS
Other Operating Expenses,2021-03-31 00:00:00,,THEMISMED.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,THEMISMED.NS
Amortization,2021-03-31 00:00:00,2184000.0,THEMISMED.NS
Depreciation Income Statement,2021-03-31 00:00:00,,THEMISMED.NS
Selling General And Administration,2021-03-31 00:00:00,161568000.0,THEMISMED.NS
Selling And Marketing Expense,2021-03-31 00:00:00,94715000.0,THEMISMED.NS
General And Administrative Expense,2021-03-31 00:00:00,66853000.0,THEMISMED.NS
Rent And Landing Fees,2021-03-31 00:00:00,8338000.0,THEMISMED.NS
Gross Profit,2021-03-31 00:00:00,,THEMISMED.NS
Cost Of Revenue,2021-03-31 00:00:00,,THEMISMED.NS
Total Revenue,2021-03-31 00:00:00,,THEMISMED.NS
Operating Revenue,2021-03-31 00:00:00,,THEMISMED.NS
